Display Settings:

Format

Send to:

Choose Destination
    Kidney Int. 2009 Nov;76(9):925-8.

    Vasopressin in chronic kidney disease: an elephant in the room?

    Source

    Mayo Clinic College of Medicine, Rochester, MN 55905, USA. torres.vicente@mayo.edu

    Abstract

    Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.

    PMID:
    19829311
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2925670
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk